कंपनी का अवलोकन
10x Genomics, Inc. (TXG) operates within the healthcare sector, specifically serving the health information services industry by developing and selling specialized instruments, consumables, and software designed for analyzing biological systems. This company serves a global customer base that spans the United States, the rest of the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific region. The enterprise currently maintains a market capitalization of $2.94 billion and employs a workforce of 1,178 individuals across its operational footprint. The annual revenue generated over the trailing twelve months stands at $642.82 million, which indicates that the market values the company at a level significantly higher than its immediate annual earnings, reflecting high expectations for future profitability or substantial investment in growth initiatives.
वित्तीय स्वास्थ्य
The company reported a revenue of $642.82 million for the trailing twelve months, yet it recorded a net income of -$43,544,000 and an EBITDA of -$64,086,000, revealing a significant gap between top-line sales and bottom-line profitability that suggests a heavy cost structure or substantial investment in R&D that has not yet translated into net earnings. Despite the negative net income and EBITDA, the firm generated free cash flow of $148.39 million, which provides the organization with notable financial flexibility to fund operations, repay debt, or invest in new technologies without relying on external financing. Profitability metrics further illustrate this challenge, with a gross margin of 69.1% indicating efficient production of goods, contrasted by an operating margin of -9.4% and a profit margin of -6.8% that highlight the substantial operating expenses eroding operational profits. The balance sheet shows a cash position of $523.41 million against total debt of $84.36 million, resulting in a debt-to-equity ratio of 10.59, which suggests the company is leveraged but maintains a robust cash buffer relative to its obligations. Liquidity is further evidenced by a current ratio of 4.46, indicating a highly conservative short-term liquidity position where current assets far exceed current liabilities. Return metrics show a return on equity of -5.8% and a return on assets of -6.4%, revealing that management has not yet been effective in generating returns on the capital invested, a common characteristic for high-growth biotech firms that are still scaling their operations.
मूल्यांकन आकलन
Valuation multiples for the stock present a complex picture, with a trailing P/E ratio marked as N/A due to negative earnings, while the forward P/E stands at 138.12, implying that the market is pricing in significant expected earnings growth to justify the current share price. The price-to-book ratio is 3.69, indicating that the market assigns a substantial premium to the company's book value, likely reflecting intangible assets such as proprietary technology and intellectual property that are not fully captured on the balance sheet. Alternative valuation metrics include a price-to-sales ratio of 4.57 and an EV/EBITDA of -39.04, suggesting that investors are valuing the company primarily on its revenue generation potential rather than current cash flow or earnings. The stock has exhibited significant price volatility, trading between a 52-week high of $23.65 and a 52-week low of $6.94, with the current price position relative to this range dependent on real-time market data not explicitly provided in the static facts. The beta value is 2.17, which means the stock price is expected to be approximately twice as volatile as the broader market, making it a high-risk investment that amplifies market movements.
Growth & Income
The financial growth profile shows a revenue growth year-over-year of 0.6%, while earnings growth is marked as N/A due to the absence of positive net income, indicating that the company is currently in a phase of revenue stabilization rather than rapid expansion or profitability scaling. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, which signifies that all available earnings are retained within the business to fund research, development, and market expansion rather than being distributed to shareholders. This reinvestment strategy is typical for early-stage life sciences companies that prioritize long-term market capture over immediate shareholder income. The overall growth and income profile is characterized by modest revenue expansion and a complete absence of dividend distributions, relying entirely on the potential for future earnings turnaround to attract capital.